/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
With a market cap of $104.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on discovering, developing, and commercializing transformative therapies for serious diseases, with a primary focus on cystic fibrosis (CF). The company also advances treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, and other conditions.
The Boston, Massachusetts-based company is slated to announce its fiscal Q3 2025 results after the market closes on Monday, Nov. 3. Ahead of the event, analysts expect Vertex Pharmaceuticals to report an adjusted EPS of $3.98, down 1.5% from $4.04 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion.
